enGene Therapeutics Inc.
ENGN- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- SEC CIK
- 0001980845
In the last 90 days, enGene Therapeutics Inc. insiders filed 1 open-market purchase and 0 sales; 60 institutions reported holding it in 13F filings for Q2 2026, worth $86.5M in total; no superinvestor holds it.
Other share classesENGNW
Q3 2025 vs. Q2 2025
How the institutions holding enGene Therapeutics Inc. changed between Q2 2025 and Q3 2025.
All holders in Q3 2025All holders in Q2 2025
| Measure | Q2 2025 | Q3 2025 | Change |
|---|---|---|---|
| Holders | 36 | 37 | +1 |
| Shares | 40.4M | 40.9M | +448.0K (+1.1%) |
| Value | $147.1M | $279.1M | +$132.0M (+89.7%) |
New holders (7)
Institutions that held enGene Therapeutics Inc. at the end of Q3 2025 but not at the end of Q2 2025.
| Institution | Shares | Value | % of portfolio |
|---|---|---|---|
| Braidwell LP | 2,266,319 | $15.5M | 0.46% |
| Perceptive Advisors LLC | 2,097,236 | $14.3M | 0.41% |
| Frazier Life Sciences Management, L.P. | 1,157,380 | $7.90M | 0.24% |
| MPM Oncology Impact Management LP | 530,299 | $3.62M | 0.59% |
| Hudson Bay Capital Management LP | 11,074 | $75.6K | 0.00% |
| PFS Partners, LLC | 9,000 | $61.5K | 0.03% |
| Citigroup Inc | 1 | $7 | 0.00% |
Sold out (6)
Institutions that held enGene Therapeutics Inc. at the end of Q2 2025 and filed for Q3 2025 without it.
| Institution | Shares, Q2 2025 | Value, Q2 2025 |
|---|---|---|
| OrbiMed Advisors LLC | 677,977 | $2.47M |
| ADAR1 Capital Management, LLC | 27,787 | $101.1K |
| Renaissance Technologies LLC | 11,400 | $41.5K |
| Paloma Partners Management Co | 10,319 | $37.6K |
| Wolverine Asset Management LLC | 6,361 | $23.2K |
| NBC Securities, Inc. | 380 | $1.00K |